 |
 |
 |
 |
| HOME | YOUR LEGAL RIGHTS | EVALUATION FORM | CONTACT US |
 |
Who We Are |
|||||
| Crestor Links | |||||
| Crestor News | |||||
|
In August 13 2003, the Food and Drug Administration (FDA) approved Crestor (rosuvastatin) to lower cholesterol. Crestor is the sixth cholesterol lowering "statin" drug on the U.S. market. The other members of the statin family are atorvastatin (lipitor), fluvastatin (lescol), lovastatin (mevacor), pravastatin (pravachol), and simvastatin (zocor). These drugs are only approved to be used along with a low-cholesterol diet and an exercise program to lower cholesterol. Another statin, cerivastatin (baycol), was removed from the market because of at least 31 reports of fatal rhabdomyolysis, an adverse reaction involving the destruction of muscle tissue that can lead to kidney failure. Rosuvastatin will be sold by AstraZeneca of Wilmington, DE under license from Shionogi & Co., Ltd., of Osaka, Japan. As reported by the consumer group Public Citizen, AstraZeneca originally filed its application with the FDA to market rosuvastatin in June 2001. The application was delayed after reports of kidney damage and muscle weakness (an early signal for rhabdomyolysis) in clinical trials in patients taking 80 milligrams of the drug per day. The company stopped development of the 80 milligram dose, and rosuvastatin will only be sold in 5, 10, 20, and 40 milligram strengths. There will also be special restrictions on the distribution of the 40 milligram strength. Public Citizen opposed the approval of rosuvastatin because it alleged that the drug causes abnormal elevations in urine protein and blood that are signals for serious kidney toxicity, and is the only statin that has shown life-threatening rhabdomyolysis in pre-approval clinical trials. Rhabdomyolysis is a potentially life-threatening condition that occurs when a large number of skeletal muscle cells die, resulting in the release of a massive amount of muscle protein (known as myogloblin) into the bloodstream. The muscle protein can become trapped in the kidneys, clogging up the filtering process of the kidneys and leading to kidney or renal failure. In addition, potassium released from the damaged muscle cells can cause malignant heart rhythms resulting in cardiac arrest. Symptoms of rhabdomyolysis include muscle pain, weakness, tenderness, malaise, fever, dark urine, nausea, and vomiting. The pain may involve specific groups of muscles or may be generalized throughout the body. If you are suffering from
rhabdomyolysis or kidney problems, and have taken Crestor, contact
Belluck & Fox for an immeidate legal evaluation. Drug litigation can
be extremely complex. It is best to seek the counsel of a personal
injury attorney with experience in this field of law. |
 |
Belluck & Fox, LLP Attorneys At Law 295 Madison Avenue, 37th Floor New York, NY 10017 (212) 681-1575 or 1-877-200-6LAW |
|
|
Attorney Advertising. Prior Results Do Not Guarantee a Similar Outcome.
Copyright © Belluck & Fox, L.L.P., Attorneys At Law, New York NY. All Rights
Reserved. Crestor Injuries, Attorneys, Lawyers, Rosuvastatin, Statin Drug,
Cholesterol Lowering Drug, Fatal Rhabdomyolysis, Kidney Failure, Muscle Tissue
Destruction, Malignant Heart Rhythms, Muscle Weakness, Damaged Muscle Cells,
Life Threatening Serving New York, Long Island, Massena, Watertown, Rochester,
Utica, ,Syracuse, Albany, Buffalo, Ithaca, Binghamton |
|